| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 70.7 | 72.5 | 76.3 |
| Other income | 2.9 | 0.1 | -1.7 |
| Total income | 73.6 | 72.6 | 74.6 |
| Profit before exceptional items & tax | 1.4 | 1.6 | 9.7 |
| Profit before tax | 1.4 | 1.6 | 9.7 |
| Net profit | 0.6 | 0.3 | 8.6 |
| Operating margin | 1.9% | 2.2% | 13.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -93.00% |
|---|---|
| Net profit, quarter on quarter | +100.00% |
| Revenue, year on year | -7.30% |
NSE results filing, NSE: BALAXI. Figures extracted from the filing.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹22.82
- Market cap
- ₹126.0 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 52.0×Sector 50.4×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Investor Presentation: Key Takeaways
Balaxi reported 14.1% YoY revenue growth in Q1 FY27, driven by market diversification and its first proprietary manufacturing facility. Strategy emphasizes backward integration in Latin America and Africa.
Balaxi Pharmaceuticals Q1 FY27 Results: Net Profit ₹1.3 Cr, Up 333.3% YoY
Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹80.7 Cr (+14.1% YoY) and net profit of ₹1.3 Cr (+333.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.3 Cr · +333.3% YoY
Balaxi Pharmaceuticals Earnings Call: Key Takeaways
Balaxi's FY26 was a transformational year focused on backward integration. Despite a 7.7% revenue decline to ₹270.17 Cr due to working capital issues in Angola, gross margins improved to 44.2%.